Patient Navigation for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, trastuzumab, and capecitabine. The program will focus on enhancing understanding of the treatment regimen, managing symptoms and adherence, and improving coping and self-management skills. If successful, the program could be integrated into clinical care to better support mBC patients. The main question the study aims to answer is: is the patient navigation program feasible and acceptable for mBC patients?
Participants will receive patient navigation sessions over about 6 weeks. Participants will also complete study assessments via electronic survey at baseline and at about 3 and 6 weeks after enrollment, with the last assessment occurring after completion of the patient navigation program sessions. Participants will also complete a post-program exit interview.
Who Is on the Research Team?
Rebecca Shelby, PhD
Principal Investigator
Duke University
Are You a Good Fit for This Trial?
This trial is for women diagnosed with HER2-positive metastatic breast cancer who can speak and read English and are currently being treated with tucatinib, trastuzumab, and capecitabine.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Patient Navigation Program
Trial Overview
The study is testing a nurse-led patient navigation program designed to help patients better understand their treatment, manage symptoms, stick to their medication schedule, and cope emotionally. The program lasts about 6 weeks alongside regular care.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
The patient navigation program will integrate 1) education to enhance understanding of the treatment regimen, follow-up care, and the importance of adherence, 2) symptom management and adherence strategies, and 3) skills and resources to enhance women's symptom coping and self-management abilities.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.